更年期潮热治疗市场-全球行业规模、份额、趋势、机会和预测，2018-2028 年，按类型、按治疗类型、按分销渠道、按地区、竞争

全球更年期潮热治疗市场预计在预测期内将出现显着增长。

这可能是由于采用替代管理方法的产品的技术进步。 此外，预计医疗保健公司对非激素药物临床试验的激增也将推动预测期内的市场增长。 此外，全球老年妇女的数量正在飙升，预计更年期潮热症状会增加。 出于这个原因，我们预计未来几年会出现显着增长。 此外，由于公共机构和私营公司的努力，女性健康意识的提高也有望刺激市场增长。 根据 2020 年 12 月发表的《女性经常潮热，40 至 65 岁患有代谢综合征》的研究，大约 55.83% 的 40 岁以上女性容易发烧，这似乎与代谢综合征有关。是。 对潮热研究和开发的日益关注也推动了市场增长。

更年期潮热增加

由于酒精、吸烟和垃圾食品消费，更年期潮热的发病率上升进一步推动了预测期内的市场增长。 此外，随着新疗法的批准，人们对新的更年期潮热疗法的认识不断提高，预计也将推动这些年来的市场增长。 美国每年约有 75-80% 的更年期妇女出现潮热。 这是一种快速变暖的感觉，主要影响胸部、颈部和麵部，也是预计推动市场增长的一些关键因素。 在女性人群中经常发现雌激素水平波动和肌肉骨骼健康状况不佳。 此外，新兴市场参与者正在投资开发新疗法，这将在预测期内进一步推动市场增长。 73% 的女性人口因疲劳、认知能力下降、睡眠障碍和生活质量下降以及医疗资源使用增加而出现绝经后潮热，预计在预测期内将继续进行更年期潮热治疗。可能需要。 85% 的更年期妇女因血管舒缩不稳定而出现继发性潮热（闪光）、盗汗和睡眠障碍。

医疗保健领域不断创新

治疗更年期潮热的医疗技术不断创新，我们正在与各大公司合作开发新设备，以帮助患有更年期潮热综合症的女性。 公司正在开发新设备以减少更年期潮热。 例如，Menopod Instant Cooler 可以涂抹在颈背上以减轻潮热的严重程度，并且是一款便携式 USB 快速充电设备。 这些用作女性个人恆温器的智能手錶型设备预计将在预测期内进一步推动市场增长。 此外，公司正在投资开发具有可调节冷却和加热温度的可定制床垫市场，预计这将在预测期内进一步推动市场增长。 2010 年，美国估计有 5000 万绝经后妇女。 根据美诺玛莎国际更年期名录，其中约有 4500 万人超过 52 岁，这是西方国家自然绝经的平均年龄。 到 2020 年，估计美国 51 岁以上的女性将超过 5000 万。

近期发展

• 美国食品和药物管理局于 2022 年 6 月接受了 Astellas Pharma Inc. 的 fesolinetant 新药申请 (NDA)。 （食品药品监督管理局）。 fesolinetant 是一种实验性口服非激素药物，正在等待批准用于治疗与更年期相关的轻度至重度血管舒缩症状 (VMS)。
• 2021 年 2 月，Astellas Pharma Inc. 宣布启动 fezolinetant 的 SKYLIGHT 1 和 SKYLIGHT 3 期关键临床试验，这是一种口服非激素化合物，正在研究用于治疗中度至重度血管舒缩症状 (VMS)。2 给予好的结果。
• 2020 年 1 月，拜耳通过收购 Vividion Therapeutics 加强了其药物发现平台。 Vividion Therapeutics 为不同的适应症生产各种小分子疗法，最初的重点是与肿瘤学和免疫学相关的靶点。

可用的自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第 5 章更年期潮热药物的全球市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按地区
  • 按公司分类（2022 年）
• 产品地图

第六章北美更年期潮热药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第7章欧洲更年期潮热药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第 8 章亚太更年期潮热治疗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第 9 章南美洲更年期潮热治疗市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第10章中东和非洲更年期潮热药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按类型（口服液/片剂）
  • 按治疗类型（激素治疗、非激素治疗、替代治疗）
  • 按分销渠道（医院药店、零售药店、在线药店）
  • 按国家
• MEA：国家分析
  • 南非更年期潮热疗法
  • 沙特更年期潮热疗法
  • 阿联酋更年期潮热治疗

第 11 章市场动态

• 司机
• 任务

第12章市场趋势与发展

• 近期发展状况
• 併购
• 产品发布

第 13 章全球更年期潮热药物市场：SWOT 分析

第 14 章波特的五力分析

• 行业竞争
• 新进入的可能性
• 供应商的力量
• 客户力量
• 替代品的威胁

第15章竞争格局

• 业务概览
• 提供的产品
• 近期发展状况
• 财务（据报导）
• 主要人物
• SWOT 分析
  • Abbvie, Inc.
  • Allergan PLC.
  • Bayer Ag.
  • Cipla, Inc.
  • Eli Lilly and Company.
  • Emcure Pharmaceuticals Ltd.
  • GSK PLC.
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Merck & Co. Inc.
  • Novartis Ag.
  • Novo Nordisk AS.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.

第16章 战略建议

Global Menopausal Hot Flashes Treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing technological advancements in products with alternative administration modes. Similarly, a rapid increase in clinical trials by healthcare companies in non-hormonal products is further expected to boost market growth during the forecast period. Moreover, a rapid increase in the number of elderly women across the globe is expected to increase menopausal hot flashes symptoms. This, in turn, is expected to create significant growth over the years. Moreover, increasing awareness about women's health on the back of public as well as private initiatives may fuel the growth of the market over the years. According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome," published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome. Growing focus on research and development of hot flashes is also driving the growth of the market.

Growing Incidences of Menopausal Hot Flashes

The growing incidence of menopausal hot flashes due to the consumption of alcohol, smoking, and junk foods is further boosting the market growth during the forecast period. Also, growing approval for new treatments, along with growing awareness about new menopausal hot flashes treatments, will drive the market growth over the years. Hot flashes occur in approximately 75 to 80% of menopausal women in the United States every year. It's a quick sensation of warmth that basically affects the chest, neck, and face and is also some of the main factors which are expected to drive market growth. High prevalence of fluctuating oestrogen levels and deteriorating musculoskeletal health among the women population. Moreover, new market players are investing in the development of new treatments, which will further boost the market growth during the forecast period. 73% of women in the women population have post-menopausal hot flashes due to fatigue, reduced cognitive function, sleep difficulties, and lowering their quality of life along with growing usage of medical resources, which will further demand menopausal hot flashes treatment during the forecast period. As many as 85% of perimenopausal women experience hot flashes (flushes), night sweats, and/or sleep disturbances secondary to vasomotor instability.

Growing Innovation in Medicine

Growing innovation in medicine for the treatment of menopausal hot flashes, along with major companies, is focusing on the development of new devices which will help women with menopausal hot flashes syndrome. Companies are developing a new device that reduces menopausal hot flashes. For instance, Menopod instant cooling devices, when applied to the neck, help alleviate the severity of hot flashes, and it is a portable, quick USB charging device. These smartwatch-like devices used as personal thermostats for women are further expected to boost the market growth during the forecast period. Moreover, companies are investing in the development of customizable mattresses that offer cooling and heating temperature controls which will further boost the market growth during the forecast period. There were an estimated 50 million postmenopausal women in the United States in 2010. According to Meno Martha International Menopause Directory, about 45 million of them were aged older than 52 years, the average age of natural menopause in the Western world. In 2020, the number of women aged more than 51 years was estimated to cross 50 million in the United States.

Market Segmentation

Global Menopausal Hot Flashes Treatment market can be segmented on the basis of type, treatment type, distribution channel, and by region. Based on type, the market can be further bifurcated into oral liquid and pill. Based on treatment type, the market can be further divided into hormonal treatment, non-hormonal treatment, and alternative treatment. Based on distribution channels, the market is further split into hospital pharmacies, retail pharmacies, and online pharmacies. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. On the basis of countries, the United States dominated the global Menopausal Hot Flashes Treatment market on account of the increasing number of women reaching menopausal age.

Recent Developments

• The U.S. Food and Drug Administration received a new drug application (NDA) for fezolinetant from Astellas Pharma Inc. in June 2022. (FDA). For the treatment of mild to severe vasomotor symptoms (VMS) related to menopause, the experimental oral, nonhormonal chemical fezolinetant is awaiting approval.
• In February 2021, Astellas Pharma Inc. announced the positive results from the Phase 3 pivotal SKYLIGHT 1 and SKYLIGHT 2 clinical trials of fezolinetant, which is an oral, non-hormonal compound being tested for the treatment of moderate to severe vasomotor symptoms (VMS).
• In January 2020, Bayer AG strengthened its drug discovery platform through the acquisition of Vividion Therapeutics. Vividion Therapeutics produces a variety of small molecule therapies across indications, and their initial focus was on targets relevant to oncology and immunology.

Market Players

Abbvie, Inc., Allergan PLC., Bayer AG., Cipla, Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GSK PLC., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., Novartis Ag., Novo Nordisk AS., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and TherapeuticsMD, Inc. are some of the leading players operating in the Global Menopausal Hot Flashes Treatment Market.

Report Scope

In this report, the global Menopausal Hot Flashes Treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Menopausal Hot Flashes Treatment Market, By Type:

• Oral Liquid
• Pill

Menopausal Hot Flashes Treatment Market, By Treatment Type:

• Hormonal Treatment
• Non-Hormonal Treatment
• Alternative Treatment

Menopausal Hot Flashes Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Menopausal Hot Flashes Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Menopausal Hot Flashes Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Oral Liquid v/s Pill)
  • 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map

6. North America Menopausal Hot Flashes Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Oral Liquid v/s Pill)
  • 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Menopausal Hot Flashes Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Oral Liquid v/s Pill)
  • 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Oral Liquid v/s Pill)
  • 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Distribution Channel

9. South America Menopausal Hot Flashes Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Oral Liquid v/s Pill)
  • 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Oral Liquid v/s Pill)
  • 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Abbvie, Inc.
  • 15.6.2 Allergan PLC.
  • 15.6.3 Bayer Ag.
  • 15.6.4 Cipla, Inc.
  • 15.6.5 Eli Lilly and Company.
  • 15.6.6 Emcure Pharmaceuticals Ltd.
  • 15.6.7 GSK PLC.
  • 15.6.8 Glenmark Pharmaceuticals Ltd.
  • 15.6.9 Hisamitsu Pharmaceutical Co. Inc.
  • 15.6.10 Merck & Co. Inc.
  • 15.6.11 Novartis Ag.
  • 15.6.12 Novo Nordisk AS.
  • 15.6.13 Pfizer, Inc.
  • 15.6.14 Teva Pharmaceutical Industries Ltd.
  • 15.6.15 TherapeuticsMD, Inc.

16. Strategic Recommendations